Skip to main content
. 2023 Apr 17;23:352. doi: 10.1186/s12885-023-10778-6

Table 2.

OS in patients with KRAS G12C or wild-type tumors with high PD-L1 (≥50%) and receiving 1L CIT alone

N Death Median OS (95% CI) Adjusted* HR (95% CI)
p-value
KRAS wild-type 65 41 10.0 (5.2–17.5) Reference
KRAS G12C 43 13 32.6 (19.4-NR)

0.57 (0.28–1.14)

p = 0.11

*Adjusted for age, sex, de novo or recurrent disease, metastasis at baseline, TMB status and histology